Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

被引:428
作者
Abida, Wassim [1 ]
Armenia, Joshua [1 ]
Gopalan, Anuradha [1 ]
Brennan, Ryan [1 ]
Walsh, Michael [1 ]
Barron, David [1 ]
Danila, Daniel [1 ]
Rathkopf, Dana [1 ]
Morris, Michael [1 ]
Slovin, Susan [1 ]
McLaughlin, Brigit [1 ]
Curtis, Kristen [1 ]
Hyman, David M. [1 ]
Durack, Jeremy C. [1 ]
Solomon, Stephen B. [1 ]
Arcila, Maria E. [1 ]
Zehir, Ahmet [1 ]
Syed, Aijazuddin [1 ]
Gao, Jianjiong [1 ]
Chakravarty, Debyani [1 ]
Vargas, Hebert Alberto [1 ]
Robson, Mark E. [1 ]
Vijai, Joseph [1 ]
Offit, Kenneth [1 ]
Donoghue, Mark T. A. [1 ]
Abeshouse, Adam A. [1 ]
Kundra, Ritika [1 ]
Heins, Zachary J. [1 ]
Penson, Alexander V. [1 ]
Harris, Christopher [1 ]
Taylor, Barry S. [1 ]
Ladanyi, Marc [1 ]
Mandelker, Diana [1 ]
Zhang, Liying [1 ]
Reuter, Victor E. [1 ]
Kantoff, Philip W. [1 ]
Solit, David B. [1 ]
Berger, Michael F. [1 ]
Sawyers, Charles L. [1 ]
Schultz, Nikolaus [1 ]
Scher, Howard I. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1200/PO.17.00029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in the disease, we performed targeted deep sequencing of tumor and normal DNA from patients with locoregional, metastatic non-castrate, and metastatic castration-resistant prostate cancer (CRPC). Methods Patients consented to genomic analysis of their tumor and germline DNA. A hybridization capture-based clinical assay was employed to identify single nucleotide variations, small insertions and deletions, copy number alterations and structural rearrangements in over 300 cancer-related genes in tumors and matched normal blood. Results We successfully sequenced 504 tumors from 451 patients with prostate cancer. Potentially actionable alterations were identified in DNA damage repair (DDR), PI3K, and MAP kinase pathways. 27% of patients harbored a germline or a somatic alteration in a DDR gene that may predict for response to PARP inhibition. Profiling of matched tumors from individual patients revealed that somatic TP53 and BRCA2 alterations arose early in tumors from patients who eventually developed metastatic disease. In contrast, comparative analysis across disease states revealed that APC alterations were enriched in metastatic tumors, while ATM alterations were specifically enriched in CRPC. Conclusion Through genomic profiling of prostate tumors representing the disease clinical spectrum, we identified a high frequency of potentially actionable alterations and possible drivers of disease initiation, metastasis and castration-resistance. Our findings support the routine use of tumor and germline DNA profiling for patients with advanced prostate cancer, for the purpose of guiding enrollment in targeted clinical trials and counseling families at increased risk of malignancy. (C) 2017 by American Society of Clinical Oncology
引用
收藏
页码:1 / 26
页数:26
相关论文
共 42 条
[1]   The Molecular Taxonomy of Primary Prostate Cancer [J].
Abeshouse, Adam ;
Ahn, Jaeil ;
Akbani, Rehan ;
Ally, Adrian ;
Amin, Samirkumar ;
Andry, Christopher D. ;
Annala, Matti ;
Aprikian, Armen ;
Armenia, Joshua ;
Arora, Arshi ;
Auman, J. Todd ;
Balasundaram, Miruna ;
Balu, Saianand ;
Barbieri, Christopher E. ;
Bauer, Thomas ;
Benz, Christopher C. ;
Bergeron, Alain ;
Beroukhim, Rameen ;
Berrios, Mario ;
Bivol, Adrian ;
Bodenheimer, Tom ;
Boice, Lori ;
Bootwalla, Moiz S. ;
dos Reis, Rodolfo Borges ;
Boutros, Paul C. ;
Bowen, Jay ;
Bowlby, Reanne ;
Boyd, Jeffrey ;
Bradley, Robert K. ;
Breggia, Anne ;
Brimo, Fadi ;
Bristow, Christopher A. ;
Brooks, Denise ;
Broom, Bradley M. ;
Bryce, Alan H. ;
Bubley, Glenn ;
Burks, Eric ;
Butterfield, Yaron S. N. ;
Button, Michael ;
Canes, David ;
Carlotti, Carlos G. ;
Carlsen, Rebecca ;
Carmel, Michel ;
Carroll, Peter R. ;
Carter, Scott L. ;
Cartun, Richard ;
Carver, Brett S. ;
Chan, June M. ;
Chang, Matthew T. ;
Chen, Yu .
CELL, 2015, 163 (04) :1011-1025
[2]  
Alexandrov LB, 2013, NATURE, V502, DOI 10.1038/nature12666
[3]   Deciphering Signatures of Mutational Processes Operative in Human Cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Campbell, Peter J. ;
Stratton, Michael R. .
CELL REPORTS, 2013, 3 (01) :246-259
[4]   Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers [J].
Aparicio, Ana M. ;
Shen, Li ;
Tapia, Elsa Li Ning ;
Lu, Jing-Fang ;
Chen, Hsiang-Chun ;
Zhang, Jiexin ;
Wu, Guanglin ;
Wang, Xuemei ;
Troncoso, Patricia ;
Corn, Paul ;
Thompson, Timothy C. ;
Broom, Bradley ;
Baggerly, Keith ;
Maity, Sankar N. ;
Logothetis, Christopher J. .
CLINICAL CANCER RESEARCH, 2016, 22 (06) :1520-1530
[5]   Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity [J].
Bajrami, Ilirjana ;
Frankum, Jessica R. ;
Konde, Asha ;
Miller, Rowan E. ;
Rehman, Farah L. ;
Brough, Rachel ;
Campbell, James ;
Sims, David ;
Rafiq, Rumana ;
Hooper, Sean ;
Chen, Lina ;
Kozarewa, Iwanka ;
Assiotis, Ioannis ;
Fenwick, Kerry ;
Natrajan, Rachael ;
Lord, Christopher J. ;
Ashworth, Alan .
CANCER RESEARCH, 2014, 74 (01) :287-297
[6]   Overcoming mutation-based resistance to antiandrogens with rational drug design [J].
Balbas, Minna D. ;
Evans, Michael J. ;
Hosfield, David J. ;
Wongvipat, John ;
Arora, Vivek K. ;
Watson, Philip A. ;
Chen, Yu ;
Greene, Geoffrey L. ;
Shen, Yang ;
Sawyers, Charles L. .
ELIFE, 2013, 2
[7]   Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer [J].
Barbieri, Christopher E. ;
Baca, Sylvan C. ;
Lawrence, Michael S. ;
Demichelis, Francesca ;
Blattner, Mirjam ;
Theurillat, Jean-Philippe ;
White, Thomas A. ;
Stojanov, Petar ;
Van Allen, Eliezer ;
Stransky, Nicolas ;
Nickerson, Elizabeth ;
Chae, Sung-Suk ;
Boysen, Gunther ;
Auclair, Daniel ;
Onofrio, Robert C. ;
Park, Kyung ;
Kitabayashi, Naoki ;
MacDonald, Theresa Y. ;
Sheikh, Karen ;
Vuong, Terry ;
Guiducci, Candace ;
Cibulskis, Kristian ;
Sivachenko, Andrey ;
Carter, Scott L. ;
Saksena, Gordon ;
Voet, Douglas ;
Hussain, Wasay M. ;
Ramos, Alex H. ;
Winckler, Wendy ;
Redman, Michelle C. ;
Ardlie, Kristin ;
Tewari, Ashutosh K. ;
Mosquera, Juan Miguel ;
Rupp, Niels ;
Wild, Peter J. ;
Moch, Holger ;
Morrissey, Colm ;
Nelson, Peter S. ;
Kantoff, Philip W. ;
Gabriel, Stacey B. ;
Golub, Todd R. ;
Meyerson, Matthew ;
Lander, Eric S. ;
Getz, Gad ;
Rubin, Mark A. ;
Garraway, Levi A. .
NATURE GENETICS, 2012, 44 (06) :685-U107
[8]   SPOP mutation leads to genomic instability in prostate cancer [J].
Boysen, Gunther ;
Barbieri, Christopher E. ;
Prandi, Davide ;
Blattner, Mirjam ;
Chae, Sung-Suk ;
Dahija, Arun ;
Nataraj, Srilakshmi ;
Huang, Dennis ;
Marotz, Clarisse ;
Xu, Limei ;
Huang, Julie ;
Lecca, Paola ;
Chhangawala, Sagar ;
Liu, Deli ;
Zhou, Pengbo ;
Sboner, Andrea ;
de Bono, Johann S. ;
Demichelis, Francesca ;
Houvras, Yariv ;
Rubin, Mark A. .
ELIFE, 2015, 4
[9]   Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination [J].
Buisson, Remi ;
Dion-Cote, Anne-Marie ;
Coulombe, Yan ;
Launay, Helene ;
Cai, Hong ;
Stasiak, Alicja Z. ;
Stasiak, Andrzej ;
Xia, Bing ;
Masson, Jean-Yves .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (10) :1247-+
[10]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404